Literature DB >> 14563385

Age and disease severity predict choice of atypical neuroleptic: a signal detection approach to physicians' prescribing decisions.

Jerome A Yesavage1, Jennifer Hoblyn, Javaid Sheikh, Jared R Tinklenberg, Art Noda, Ruth O'Hara, Catherine Fenn, Martin S Mumenthaler, Leah Friedman, Helena C Kraemer.   

Abstract

OBJECTIVE: We used a novel application of a signal detection technique, receiver operator characteristics (ROC), to describe factors entering a physician's decision to switch a patient from a typical high potency neuroleptic to a particular atypical, olanzapine (OLA) or risperidone (RIS).
METHODS: ROC analyses were performed on pharmacy records of 476 VA patients who had been treated on a high potency neuroleptic then changed to either OLA or RIS.
RESULTS: Overall 68% patients switched to OLA and 32% to RIS. The best predictor of neuroleptic choice was age at switch, with 78% of patients aged less than 55 years receiving OLA and 51% of those aged greater than or equal to 55 years receiving OLA (chi(2)=38.2, P<0.001). Further analysis of the former group indicated that adding the predictor of one or more inpatient days to age increased the likelihood of an OLA switch from 78% to 85% (chi(2)=7.3, P<0.01) while further analysis of the latter group indicated that adding the predictor of less than 10 inpatients days to age decreased the likelihood of an OLA switch from 51% to 45% (chi(2)=7.0, P<0.01).
CONCLUSIONS: ROC analyses have the advantage over other analyses, such as regression techniques, insofar as their "cut-points" are readily interpretable, their sequential use forms an intuitive "decision tree" and allows the potential identification of clinically relevant "subgroups". The software used in this analysis is in the public domain (http://mirecc.stanford.edu).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563385     DOI: 10.1016/s0022-3956(03)00053-0

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  5 in total

1.  Donepezil treatment in ethnically diverse patients with Alzheimer disease.

Authors:  Jared R Tinklenberg; Helena C Kraemer; Kristine Yaffe; Ruth O'Hara; John M Ringman; John W Ashford; Jerome A Yesavage; Joy L Taylor
Journal:  Am J Geriatr Psychiatry       Date:  2014-09-28       Impact factor: 4.105

2.  Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.

Authors:  Jerome H Taylor; Ewgeni Jakubovski; Daniel Gabriel; Michael H Bloch
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-06-19       Impact factor: 2.576

3.  Choice of atypical antipsychotic therapy for patients with schizophrenia: An analysis of a medicaid population.

Authors:  Gordon G Liu; Shawn X Sun; Dale B Christensen; Zhongyun Zhao
Journal:  Curr Ther Res Clin Exp       Date:  2005-09

4.  Predictors of Response to Behavioral Treatments Among Children With ADHD-Inattentive Type.

Authors:  Elizabeth B Owens; Stephen P Hinshaw; Keith McBurnett; Linda Pfiffner
Journal:  J Clin Child Adolesc Psychol       Date:  2016-11-02

5.  DTI measures identify mild and moderate TBI cases among patients with complex health problems: A receiver operating characteristic analysis of U.S. veterans.

Authors:  Keith L Main; Salil Soman; Franco Pestilli; Ansgar Furst; Art Noda; Beatriz Hernandez; Jennifer Kong; Jauhtai Cheng; Jennifer K Fairchild; Joy Taylor; Jerome Yesavage; J Wesson Ashford; Helena Kraemer; Maheen M Adamson
Journal:  Neuroimage Clin       Date:  2017-06-24       Impact factor: 4.881

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.